CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
CO33: Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
CommNETs hosted a virtual research workshop 10, 11, 16 and 17 February 2021 including a main conference event and five satellite project working group sessions. Thanks to the strong engagement of CommNETs collaborators, progress was made for planned work on existing projects and advancement of new ideas. CommNETs relies on the commitment of colleagues and partners to connect and lead research, and the continued collective effort of this group was evident through the excellent participation at the 2021 Virtual Research Workshop.
The SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT): The Phase III Randomized Controlled Trial CCTG HN11 has successfully received $3,203,435 in funding from the Canadian Institutes of Health Research in the Fall Research competition.
Congratulations to Dr. Tricia Cottrell, a CCTG Senior Investigator, has been awarded $872,86 to support the IND227 study from the Canadian Institutes of Health Research (CIHR) Fall Project Competition.
Malignant Pleural Mesothelioma is rare and deadly form of cancer. Patients do not respond well to the current standard of care. However, there have been some positive results using immunotherapy. Immunotherapy is a new way of treating cancer that “turns on” an individual’s anticancer immune response.
Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received an additional $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Fall 2020 competition matching funds awarded in the spring from this program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada.
A Canadian team, Dr. Rebecca Auer Surgical Oncologist & Director of Cancer Research, The Ottawa Hospital and Dr. Chris O’Callaghan, Senior Investigator of the Canadian Cancer Trials Group are researching how we can strengthen the immune system of cancer patients to better protect them against COVID-19.
ExCELLirate Canada, led by the Canadian Cancer Trials Group (CCTG) at Queen’s University, has received $5,187,685 to develop a national research platform to coordinate the development of new cancer cell therapies. This will be a comprehensive national research, development and testing platform that will benefit patients, healthcare providers, and industry by ensuring Canadian cell therapy innovations are safely, cost effectively and efficiently manufactured.
The Cancer Research Study Coordinator works within a team based structure to coordinate and oversee national, international and cooperative oncology group, multi-centre, multi-modality clinical trials in cancer therapy, prevention and supportive care.
